United States v. John Gladden

78 F.4th 1232
CourtCourt of Appeals for the Eleventh Circuit
DecidedAugust 17, 2023
Docket21-11621
StatusPublished
Cited by13 cases

This text of 78 F.4th 1232 (United States v. John Gladden) is published on Counsel Stack Legal Research, covering Court of Appeals for the Eleventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. John Gladden, 78 F.4th 1232 (11th Cir. 2023).

Opinion

USCA11 Case: 21-11621 Document: 110-1 Date Filed: 08/17/2023 Page: 1 of 34

[PUBLISH] In the United States Court of Appeals For the Eleventh Circuit

____________________ No. 21-11621 ____________________

UNITED STATES OF AMERICA, Plaintiff-Appellee, versus JOHN GLADDEN, JESSICA LINTON,

Defendants-Appellants.

____________________

Appeals from the United States District Court for the Northern District of Alabama D.C. Docket No. 6:19-cr-00219-LSC-SGC-7 ____________________ USCA11 Case: 21-11621 Document: 110-1 Date Filed: 08/17/2023 Page: 2 of 34

21-11621 Opinion of the Court 2

Before WILSON, JILL PRYOR, Circuit Judges, and COVINGTON,∗ District Judge. COVINGTON, District Judge: Jessica Linton and John Gladden were convicted of conspiracy to commit health care fraud and mail fraud, and the substantive offenses of health care fraud, mail fraud, and aggravated identity theft, for their roles in a multi-year scheme to defraud insurance companies. Linton, Gladden, and several others at Global Compounding Pharmacy received inflated reimbursement payments by billing for medically unnecessary and fraudulent prescriptions. Linton and Gladden now appeal their convictions. In addition, Gladden appeals the district court’s restitution and forfeiture orders. For the following reasons, we affirm as to Linton and affirm in part, vacate in part, and remand as to Gladden. I Global Compounding Pharmacy began operations in 2014. In its first two years of existence, Global billed approximately $193 million to pharmacy benefit managers (PBMs) and received over $49 million in reimbursement payments from PBMs and insurance companies. As it turns out, Global’s success was attributable to a company-wide scheme to defraud pharmacy networks by secretly

∗ Honorable Virginia M. Covington, United States District Judge for the

Middle District of Florida, sitting by designation. USCA11 Case: 21-11621 Document: 110-1 Date Filed: 08/17/2023 Page: 3 of 34

21-11621 Opinion of the Court 3

billing PBMs for medically unnecessary and fraudulent prescriptions. When it began operations, Global focused on filling prescriptions for compounded drugs, which are supposed to be personalized medications for patients with individual needs. The reimbursement rates for these drugs are very high: Global could be reimbursed as much as $20,000 for a single tube of a compounded cream. Global employees thus saw an opportunity to generate significant revenue by dispensing more compounded drugs. Whether the patients actually had a medical need for these drugs was of little concern. The underlying conspiracy at Global, which is not in dispute, relied on the following methods: adding non-prescribed items to prescription forms; incentivizing or paying prescribers to write medically unnecessary prescriptions; directing employees to obtain high-reimbursement, medically unnecessary prescriptions; billing for unauthorized or forged prescriptions; altering prescriptions to increase revenue; automatically refilling medications; inflating the average wholesale price of ingredients for compounded drugs; hiring sales representatives who were close to prescribers; adding or removing ingredients from compounded drugs to increase profits; reducing co-pays to induce beneficiaries to obtain medically unnecessary prescriptions; and providing false information to PBMs during audits. A PBM is a company that acts as an intermediary between pharmacies and insurance companies. Typically, an insurance USCA11 Case: 21-11621 Document: 110-1 Date Filed: 08/17/2023 Page: 4 of 34

21-11621 Opinion of the Court 4

company beneficiary visits his or her doctor, the doctor prescribes the beneficiary a prescription drug, and then the beneficiary visits a pharmacy to fill the prescription. Once the patient brings the prescription to a pharmacy, the pharmacy inputs the information into the pharmacy processing system, which communicates with the PBM. The PBM checks whether the drug is covered and determines the beneficiary’s co-pay. The PBM shares this information with the pharmacy, so that the pharmacy can collect the co-pay and dispense the drug. A. Jessica Linton’s Role As the manager of the billing department at the Clearwater Call Center, Jessica Linton played an integral role in the scheme at Global. First, Linton and other billers at the Clearwater Call Center would run “dummy claims” to identify products covered by insurance. The billing department would submit test claims for prescriptions to an insurance company to see whether the company would reimburse the product, and then claw back the claim. Linton would proceed to solicit Global employees to obtain prescriptions for the most lucrative products. Second, Linton used Global’s preprinted prescription forms to add and change prescriptions without the approval of the prescribing doctors. For example, on January 6, 2015, Global sales representative Joshlyn Bowen emailed Linton about a prescription for her husband, Robert Cody Bowen. Dr. John Almirol, who treated Robert Bowen as a patient, issued the prescription. In USCA11 Case: 21-11621 Document: 110-1 Date Filed: 08/17/2023 Page: 5 of 34

21-11621 Opinion of the Court 5

response to Joshlyn Bowen’s email, Linton stated that she received the prescription, and confirmed, “[j]ust pain and migraine cream is all he needs?” Joshlyn Bowen then asked Linton to add additional medication to the prescriptions—without consulting Dr. Almirol. Linton did just that. Third, Linton directed employees to obtain prescriptions for products that the patients would not—or should not—use. For example, Jamey Mays, Global’s lead pharmacist, testified that he and Linton emailed about a scar patch for which he had received a prescription. In an email to Linton regarding whether to reverse the prescription, Mays wrote “you can leave it. It is working really well,” followed by a winking smiley face. In fact, Mays had never received the product. Nor could he have, because as Linton was well aware, the product had been discontinued. This was not the only time Linton authorized the filling of prescriptions for products that would never be used. In June 2015, Linton sent a text message to Angie Nelson, a Global district manager, about a skin treatment medication called SilaPak that had been prescribed to Nelson’s child. Linton’s text message read “hey girl, Jamey [Mays] is not comfortable with [patients] under 6 using SilaPak. He said he’d let [Nelson’s daughter’s] order ship as long as you don’t actually use it on her.” As mentioned before, automatic refills were part of Global’s scheme. But eventually, some patients began to take issue with the surplus of products they were receiving through automatic refills. Linton had a solution: reroute the medications of dissatisfied USCA11 Case: 21-11621 Document: 110-1 Date Filed: 08/17/2023 Page: 6 of 34

21-11621 Opinion of the Court 6

customers to the address of Jeremy Adams, Global’s owner. That way, Global could continue to bill insurance for the refilled prescriptions that were no longer wanted by the actual patients. Donald Edenfield, the former husband of Lori Dawn Edenfield, a nurse practitioner relied upon by Global, testified that he had received several refills of compounded creams from Global, even though he did not need them, had not requested the refills, and did not submit co-pays for the refills. Donald Edenfield contacted Lori Dawn Edenfield to request that Global stop sending him the creams. This seemed to work: Donald Edenfield no longer received the creams at his address. However, Global subsequently issued a prescription in Donald Edenfield’s name for the compounded creams, but with the shipping address on the prescription labels listed as Jeremy Adams’ address. Of course, Donald Edenfield did not live with Jeremy Adams.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Andrea Mitchell
Eleventh Circuit, 2026
United States v. McGonigle
Ninth Circuit, 2025
United States v. Joff Philossaint
141 F.4th 1334 (Eleventh Circuit, 2025)
United States v. Joe May
131 F.4th 633 (Eighth Circuit, 2025)
United States v. Anita Jackson
Fourth Circuit, 2025
United States v. Eric King
126 F.4th 440 (Sixth Circuit, 2025)
United States v. Andrew Butler, III
117 F.4th 1309 (Eleventh Circuit, 2024)
United States v. Conley
89 F.4th 815 (Tenth Circuit, 2023)
United States v. Croft
87 F.4th 644 (Fifth Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
78 F.4th 1232, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-john-gladden-ca11-2023.